Autocrine VEFG loops, signaling pathways, and acute leukemia regulation

Leukemia and Lymphoma

Volumn 48, Issue 3, 2007, Pages 481-488

  Fragoso, Rita ^a,b   Elias, Ana Paula ^a,b   Dias, Sérgio ^a,b  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

Author keywords

Angiogenesis; Leukemia; VEGF; VEGF receptors

Indexed keywords

ARSENIC TRIOXIDE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C; THALIDOMIDE; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE LEUKEMIA; AUTOCRINE EFFECT; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL MIGRATION; DISEASE COURSE; DRUG MECHANISM; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION; LEUKEMIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; AUTOCRINE COMMUNICATION; HUMANS; LEUKEMIA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33947642080     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601064720     Document Type: Review

References (72)

1. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246, pp. 1306-1309.
2. Perez-Atayde, A. R., Sallan, S. E., Tedrow, U., Connors, S., Allred, E. and Folkman, J. (1997) Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol, 150, pp. 815-821.
3. Yetgin, S., Yenicesu, I., Cetin, M. and Tuncer, M. (2001) Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma, 42, pp. 83-88.
4. Hanahan, D. and Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, pp. 353-364.
5. Fiedler, W., Graeven, U., Ergun, S., Verago, S., Kilic, N. and Stockschlader, M. (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood, 89, pp. 1870-1875.
6. Aguayo, A., Estey, E., Kantarjian, H., Mansouri, T., Gidel, C. and Keating, M. (1999) Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94, pp. 3717-3721.
7. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E. and Thomas, D. (2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96, pp. 2240-2245.
8. Padro, T., Ruiz, S., Bieker, R., Burger, H., Steins, M. and Kienast, J. (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 95, pp. 2637-2644.
9. Hussong, J. W., Rodgers, G. M. and Shami, P. J. (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood, 95, pp. 309-313.
10. de Bont, E. S., Rosati, S., Jacobs, S., Kamps, W. A. and Vellenga, E. (2001) Increased bone marrow vascularization in patients with acute myeloid leukaemia: A possible role for vascular endothelial growth factor. Br J Haematol, 113, pp. 296-304.
11. Ghannadan, M., Wimazal, F., Simonitsch, I., Sperr, W. R., Mayerhofer, M. and Sillaber, C. (2003) Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. Am J Clin Pathol, 119, pp. 663-671.
12. Brunner, B., Gunsilius, E., Schumacher, P., Zwierzina, H., Gastl, G. and Stauder, R. (2002) Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res, 11, pp. 119-125.
13. Lundberg, L. G., Lerner, R., Sundelin, P., Rogers, R., Folkman, J. and Palmblad, J. (2000) Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol, 157, pp. 15-19.
14. Verstovsek, S., Lunin, S., Kantarjian, H., Manshouri, T., Faderl, S. and Cortes, J. (2003) Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res, 27, pp. 661-669.
15. Chen, H., Treweeke, A. T., West, D. C., Till, K. J., Cawley, J. C. and Zuzel, M. (2000) In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood, 96, pp. 3181-3187.
16. Koomagi, R., Zintl, F., Sauerbrey, A. and Volm, M. (2001) Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res, 7, pp. 3381-3384.
17. Dey, A. L., Yang, Y., Shen, Y., Jilani, I. B. and Estey, E. H. (2004) Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer, 100, pp. 1884-1891.
18. Bellamy, W. T., Richter, L., Frutiger, Y. and Grogan, T. M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res, 59, pp. 728-733.
19. Padro, T., Bieker, R., Ruiz, S., Steins, M., Retzlaff, S. and Burger, H. (2002) Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia, 16, pp. 1302-1310.
20. Dias, S., Hattori, K., Zhu, Z., Heissig, B., Choy, M. and Lane, W. (2000) Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest, 106, pp. 511-521.
21. Aguayo, A., Kantarjian, H. M., Estey, E. H., Giles, F. J., Verstovsek, S. and Manshouri, T. (2002) Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer, 95, pp. 1923-1930.
22. de Bont, E. S., Fidler, V., Meeuwsen, T., Scherpen, F., Hahlen, K. and Kamps, W. A. (2002) Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res, 8, pp. 2856-2861.
23. Faderl, S., Do, K. A., Johnson, M. M., Keating, M., O'Brien, S. and Jilani, I. (2005) Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood, 106, pp. 4303-4307.
24. Molica, S., Vacca, A., Levato, D., Merchionne, F. and Ribatti, D. (2004) Angiogenesis in acute and chronic lymphocytic leukemia. Leuk Res, 28, pp. 321-324.
25. Frankel, A. E. and Gill, P. S. (2004) VEGF and myeloid leukemias. Leuk Res, 28, pp. 675-677.
26. Aguayo, A., Giles, F. and Albitar, M. (2003) Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma, 44, pp. 213-222.
27. Liu, P., Wang, Y., Li, Y. H., Yang, C. and Zhou, Y. L. (2003) Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leuk Res, 27, pp. 701-708.
28. Lai, R., Estey, E., Shen, Y., Despa, S., Kantarjian, H. and Beran, M. (2002) Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer, 94, pp. 14-17.
29. Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, pp. 843-845.
30. Levy, A. P., Levy, N. S., Wegner, S. and Goldberg, M. A. (1995) Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem, 270, pp. 13333-13340.
31. Liu, Y., Cox, S. R., Morita, T. and Kourembanas, S. (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res, 77, pp. 638-643.
32. Jiang, B. H., Agani, F., Passaniti, A. and Semenza, G. L. (1997) V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. Cancer Res, 57, pp. 5328-5335.
33. Shi, Q., Abbruzzese, J. L., Peng, Z., Qian, C. N. and Tang, H. (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res, 61, pp. 4143-4154.
34. Deroanne, C. F., Hajitou, A., Calberg-Bacq, C. M., Nusgens, B. V. and Lapiere, C. M. (1997) Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res, 57, pp. 5590-5597.
35. Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H. A. and Kohno, K. (1996) Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem, 271, pp. 28220-28228.
36. Pertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N. and Saksela, O. (1994) Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem, 269, pp. 6271-6274.
37. Goad, D. L., Rubin, J., Wang, H., Tashjian Jr, A. H. and Patterson, C. (1996) Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. Endocrinology, 137, pp. 2262-2268.
38. Perrella, M. A., Tsai, J. C., Yet, S. F., Hsieh, C. M. and Yoshizumi, M. (1995) Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem, 270, pp. 308-312.
39. Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G. and Levi, B. Z. (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem, 271, pp. 736-741.
40. Matsumoto, K., Ohi, H. and Kanmatsuse, K. (1997) Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron, 77, pp. 212-218.
41. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G. and Marme, D. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res, 56, pp. 2299-2301.
42. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Huang, H J Su, de Tribolet, N. and Cavenee, W. K. (1994) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet, 8, pp. 171-176.
43. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S. and Sukhatme, V. P. (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol, 17, pp. 5629-5639.
44. Teodoro, J. G., Parker, A. E., Zhu, X. and Green, M. R. (2006) p53-Mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science, 313, pp. 968-971.
45. Scortegagna, M., Morris, M. A., Oktay, Y., Bennett, M. and Garcia, J. A. (2003) The HIF family member EPAS1/HIF-2α is required for normal hematopoiesis in mice. Blood, 102, pp. 1634-1640.
46. Mortensen, B. T., Jensen, P. O., Helledie, N., Iversen, P. O., Ralfkiaer, E. and Larsen, J. K. (1998) Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol, 102, pp. 458-464.
47. Wellmann, S., Guschmann, M., Griethe, W., Eckert, C., von Stackelberg, A. and Lottaz, C. (2004) Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia, 18, pp. 926-933.
48. Mayerhofer, M., Valent, P., Sperr, W. R., Griffin, J. D. and Sillaber, C. (2002) BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1α, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood, 100, pp. 3767-3775.
49. Narendran, A., Ganjavi, H., Morson, N., Connor, A., Barlow, J. W. and Keystone, E. (2003) Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol, 31, pp. 693-701.
50. Dias, S., Choy, M., Alitalo, K. and Rafii, S. (2002) Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood, 99, pp. 2179-2184.
51. Bellamy, W. T. (2001) Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol, 28, pp. 551-559.
52. Allouche, M., Bayard, F., Clamens, S., Fillola, G., Sie, P. and Amalric, F. (1995) Expression of basic fibroblast growth factor (bFGF) and FGF-receptors in human leukemic cells. Leukemia, 9, pp. 77-86.
53. Katoh, O., Takahashi, T., Oguri, T., Kuramoto, K., Mihara, K. and Kobayashi, M. (1998) Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res, 58, pp. 5565-5569.
54. Gerber, H. P., Malik, A. K., Solar, G. P., Sherman, D., Liang, X. H. and Meng, G. (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature, 417, pp. 954-958.
55. Santos, S. C. and Dias, S. (2004) Internal and external autocrine VEGF/ KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood, 103, pp. 3883-3889.
56. Dias, S., Shmelkov, S. V., Lam, G. and Rafii, S. (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood, 99, pp. 2532-2540.
57. Wang, L., Chen, L., Benincosa, J., Fortney, J. and Gibson, L. F. (2005) VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli. Leukemia, 19, pp. 344-353.
58. List, A. F., Glinsmann-Gibson, B., Stadheim, C., Meuillet, E. J., Bellamy, W. and Powis, G. (2004) Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol, 32, pp. 526-535.
59. Fragoso, R., Pereira, T., Zhu, Z., Cabecadas, J. and Dias, S. (2006) VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood, 107, pp. 1608-1616.
60. Dias, S., Hattori, K., Heissig, B., Zhu, Z. and Witte, L. (2001) Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc Natl Acad Sci USA, 98, pp. 10857-10862.
61. Zhang, H., Bassi, R., Jimenez, X. and Witte, L. (2004) Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human antibody directed against vascular endothelial growth factor receptor 2. Leuk Lymphoma, 45, pp. 1887-1897.
62. Hanahan, D., Bergers, G. and Bergsland, E. (2000) Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest, 105, pp. 1045-1047.
63. Bartlett, J. B., Dredge, K. and Dalgleish, A. G. (2004) The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer, 4, pp. 314-322.
64. Hayashi, T., Hideshima, T. and Anderson, K. C. (2003) Novel therapies for multiple myeloma. Br J Haematol, 120, pp. 10-17.
65. Steins, M. B., Padro, T., Bieker, R., Ruiz, S., Kropff, M. and Kienast, J. (2002) Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood, 99, pp. 834-839.
66. Thomas, D. A., Estey, E., Giles, F. J., Faderl, S., Cortes, J. and Keating, M. (2003) Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol, 123, pp. 436-441.
67. Roboz, G. J., Dias, S., Lam, G., Lane, W. J., Soignet, S. L. and Warrell Jr, R. P. (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 96, pp. 1525-1530.
68. Park, M. J., Park, I. C., Bae, I. J., Seo, K. M., Lee, S. H. and Hong, S. I. (2003) Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol, 22, pp. 1271-1276.
69. Kini, A. R., Peterson, L. A., Tallman, M. S. and Lingen, M. W. (2001) Angiogenesis in acute promyelocytic leukemia: Induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood, 97, pp. 3919-3924.
70. Fiedler, W., Mesters, R., Tinnefeld, H., Loges, S., Staib, P. and Duhrsen, U. (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood, 102, pp. 2763-2767.
71. Giles, F. J., Cooper, M. A., Silverman, L., Karp, J. E., Lancet, J. E. and Zangari, M. (2003) Phase II study of SU5416-a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer, 97, pp. 1920-1928.
72. Giles, F. J., Stopeck, A. T., Silverman, L. R., Lancet, J. E., Cooper, M. A. and Hannah, A. L. (2003) SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood, 102, pp. 795-801.